ArticleLa Radiologia medica2025
Fluoroscopy-guided transvenous femoral renal transplant biopsies: a monocentric retrospective study about 109 consecutive patients.
Article in La Radiologia medica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesRenal transplant biopsy remains the gold standard for etiological diagnosis of graft dysfunction and subsequent management. When percutaneous renal biopsy (PRB) is contraindicated due to bleeding risk or limited percutaneous access, the fluoroscopy-guided transvenous femoral renal transplant biopsy (TFRB) might be a valuable alternative. This study aims to describe the TFRB technique, its safety, and efficacy.
methodsAll patients who underwent TFRB at our institution between 2020 and 2023 were retrospectively analyzed. Procedure outcomes, patients' characteristics and follow-up data were collected. Adverse events were graded using the Adverse Events Classification of the Society of Interventional Radiology.
resultsFrom January 2020 to December 2023, 109 patients (median age 61.2 years (Interquartile range (IQR), 54.5-68.6) ; 49 males (45.0%)) underwent 122 TFRB. Transvenous approach was indicated due to high bleeding risk in 61.5% (75/122), limited percutaneous access in 13.9% (17/122), or previous failed PRB in 2.5% (3/122). Biopsy success rate was 94.3%, with 7 graft vein catheterization failures. Adequate Banff 97 criteria specimens were obtained in 68.7% of cases, and a definitive histological diagnosis was achieved in 96.5% of biopsies. Complications occurred in 20.0% of procedures (23/115), including 9 major complications (7.8%), with no significant difference according to the TFRB indication (bleeding risk versus percutaneous limited access) (p = 0.70), use of antiplatelet agents (p = 0.24) or anticoagulants (p = 1.00).
conclusionThis is the first large cohort study to demonstrates TFRB to be effective and safe in case of contraindication to PRB, providing valuable insights for graft dysfunction management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.